Bank of America raises target to USD 29 for Pfizer stock

Published on 10/21/2026 at 11:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 15.03 billion in the second quarter, 2.60 percent above 2025. Pfizer stock costs EUR 26.71 on October 21, 2026 versus EUR 26.81 Xetra close.

Analyst view and operating evidence

Bank of America raised its Pfizer target from USD 27.00 to USD 29.00 on October 9, 2026.
Second-quarter revenue reached USD 15.03 billion, up 2.60 percent year over year.
Pfizer stock trades at EUR 26.71 at 11:51 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.37 percent below the Xetra close of October 20, 2026.

Editorialfoto eines Trading-Floors mit Sektor-Charts, Symbolbild für den Aktienhandel von Pfizer Inc — Börsen-Editorialfoto vom Trading-Floor mit Pharma-Charts steht sinnbildlich für den Aktienhandel von Pfizer Inc., ISIN US7170811035, Illustration mit AI erstellt.

Pfizer Inc. stock (ISIN US7170811035) was trading at EUR 26.71 at Lang & Schwarz on October 21, 2026, at 11:51 a.m. CEST, down 0.37 percent versus the Xetra close of October 20, 2026 at EUR 26.81. The latest analyst action came from Bank of America, whose analyst Jason Gerberry raised the price target from USD 27.00 to USD 29.00 on October 9, 2026, while keeping a Neutral rating, as Markets Insider reported.

Three dates shape the case

On August 4, 2026, Pfizer reported second-quarter revenue of USD 15.03 billion and adjusted earnings per share of USD 0.77, compared with consensus revenue of USD 14.40 billion and consensus adjusted earnings per share of USD 0.68, according to MarketBeat. On October 6, 2026, Pfizer declared a quarterly dividend of USD 0.43 per common share. On October 9, 2026, Bank of America lifted its target to USD 29.00 from USD 27.00, a move documented by Markets Insider.

What does the target mean?

The target revision sits against a mixed earnings picture. Second-quarter revenue rose 2.60 percent year over year to USD 15.03 billion, but Pfizer reported a GAAP net loss of USD 246.00 million for the period, according to MarketBeat. Pfizer set fiscal 2026 adjusted earnings-per-share guidance at USD 2.80 to USD 3.00, keeping execution and pipeline progress central to the valuation discussion.

Next scheduled company date

Pfizer lists a November 3, 2026 webcast for its conference call with analysts on its official website, which also identifies the company as a global biopharmaceutical business focused on medicines and vaccines: Pfizer.

Stock remains below the Xetra close

Pfizer stock was trading at EUR 26.71 at Lang & Schwarz on October 21, 2026, at 11:51 a.m. CEST, 0.37 percent below the Xetra close of October 20, 2026 at EUR 26.81. The primary listing is on the NYSE, where Pfizer was last quoted at USD 30.11 on October 20, 2026 at 4:02 p.m. ET; the 52-week range was USD 23.62 to USD 30.25.

The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.